MARKET

ALIM

ALIM

Alimera Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3592
-0.0042
-1.14%
Closed 16:00 10/17 EDT
OPEN
0.3706
PREV CLOSE
0.3633
HIGH
0.3879
LOW
0.3400
VOLUME
137.07K
TURNOVER
--
52 WEEK HIGH
1.210
52 WEEK LOW
0.3210
MARKET CAP
25.50M
P/E (TTM)
0.9562
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALIM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ALIM News

  • Alimera Reports Marketing Authorization for ILUVIEN In Portugal For Treatment Of Non-Infectious Posterior Uveitis
  • Benzinga.10/03 12:41
  • Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis
  • GlobeNewswire.10/03 12:30
  • Alimera Sees Prelim. Q3 Sales Exceeding $12.8M
  • Benzinga.10/02 12:06
  • Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019
  • GlobeNewswire.10/02 12:00

More

Industry

Pharmaceuticals
+0.54%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Name
Price
%Change

About ALIM

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
More

Webull offers Alimera Sciences Inc (ALIM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.